argenex (NASDAQ:ARGX) Price Target Raised to $1,190.00

by · The Cerbat Gem

argenex (NASDAQ:ARGX – Free Report) had its price objective hoisted by Morgan Stanley from $1,140.00 to $1,190.00 in a report published on Friday,Benzinga reports. They currently have an overweight rating on the stock.

Several other equities research analysts have also issued reports on ARGX. UBS Group raised shares of argenex from a “neutral” rating to a “buy” rating and increased their target price for the stock from $960.00 to $1,400.00 in a report on Wednesday, August 26th. JPMorgan Chase & Co. restated a “buy” rating on shares of argenex in a research note on Wednesday, August 5th. HC Wainwright lifted their price target on shares of argenex from $940.00 to $1,202.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Wedbush dropped their price target on shares of argenex from $1,150.00 to $1,130.00 and set an “outperform” rating for the company in a research report on Thursday, October 8th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of argenex in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, argenex currently has an average rating of “Moderate Buy” and an average target price of $1,142.37.

Check Out Our Latest Stock Analysis on ARGX

argenex Price Performance

Shares of ARGX opened at $873.71 on Friday. The business has a 50-day simple moving average of $956.62 and a two-hundred day simple moving average of $886.34. The stock has a market cap of $54.95 billion, a price-to-earnings ratio of 30.49, a PEG ratio of 0.89 and a beta of 0.44. argenex has a 52 week low of $661.85 and a 52 week high of $1,072.75.

argenex (NASDAQ:ARGX – Get Free Report) last posted its quarterly earnings data on Friday, October 23rd. The company reported $7.80 EPS for the quarter, topping the consensus estimate of $7.44 by $0.36. argenex had a return on equity of 47.70% and a net margin of 31.66%. The firm had revenue of $1.75 billion for the quarter. On average, equities analysts anticipate that argenex will post 25.79 earnings per share for the current fiscal year.

Institutional Trading of argenex

Institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC raised its stake in argenex by 3.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock valued at $1,847,592,000 after purchasing an additional 83,568 shares during the period. Jennison Associates LLC lifted its holdings in argenex by 3.4% in the 1st quarter. Jennison Associates LLC now owns 237,468 shares of the company’s stock worth $173,411,000 after purchasing an additional 7,707 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in argenex by 1.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 175,311 shares of the company’s stock worth $130,277,000 after purchasing an additional 2,579 shares in the last quarter. First Trust Advisors LP boosted its stake in argenex by 98.9% in the 1st quarter. First Trust Advisors LP now owns 107,195 shares of the company’s stock worth $78,279,000 after purchasing an additional 53,293 shares during the period. Finally, Eagle Health Investments LP boosted its stake in argenex by 21.7% in the 1st quarter. Eagle Health Investments LP now owns 76,336 shares of the company’s stock worth $55,744,000 after purchasing an additional 13,606 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Key Stories Impacting argenex

Here are the key news stories impacting argenex this week:

  • Positive Sentiment: Strong quarterly results: argenx reported $7.80 in EPS, exceeding the $7.44 consensus estimate, while revenue reached $1.75 billion. Product net sales grew 54% year over year to $1.7 billion, and operating profit was $486 million. argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
  • Positive Sentiment: Bullish analyst support: Morgan Stanley raised its price target from $1,140 to $1,190 and maintained an “overweight” rating. Wells Fargo also maintained “overweight” despite trimming its target from $1,356 to $1,336. Jefferies called the post-news setup a potentially attractive entry point. Morgan Stanley rating
  • Neutral Sentiment: Targets remain above the market price, but revisions are mixed: Guggenheim lowered its target from $1,185 to $1,120 while keeping a “buy” rating. Robert W. Baird raised its target from $823 to $861 but retained a “neutral” rating, and RBC reportedly cut its target. These changes suggest continued confidence in long-term value but more cautious near-term expectations. Guggenheim rating
  • Negative Sentiment: Clinical-development setback is overshadowing the earnings beat: Reports highlighted a surprise testing setback for argenx’s core drug, raising concerns about future growth, product expansion and execution. That issue appears to be driving the weaker investor reaction despite the company’s strong sales and profitability. argenx testing setback

argenex Company Profile

(Get Free Report)

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.

Further Reading